These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22562075)

  • 1. Why do we need biomarkers in solid organ transplantation.
    Olbricht CJ
    Clin Chim Acta; 2012 Sep; 413(17-18):1310-1. PubMed ID: 22562075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimization of immunosuppressive therapy and immunological monitoring of kidney transplant recipients with long-term allograft survival.
    Pretagostini R; Cinti P; Lai Q; Poli L; Berloco PB
    Transpl Immunol; 2008 Nov; 20(1-2):3-5. PubMed ID: 18773959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Future trends in organ transplant recipients--important issues for dermatologists.
    Zecher D; Steiger J
    Curr Probl Dermatol; 2012; 43():71-80. PubMed ID: 22377921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunopharmacologic therapy in renal transplantation.
    Shoker AS
    Pharmacotherapy; 1996; 16(4):562-75. PubMed ID: 8840362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New directions for induction immunosuppression strategy in solid organ transplantation.
    Hawksworth JS; Leeser D; Jindal RM; Falta E; Tadaki D; Elster EA
    Am J Surg; 2009 Apr; 197(4):515-24. PubMed ID: 19249743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
    Helal I; Chan L
    Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of the immunomodulatory effect of immunosuppressive drugs in transplant recipients.
    Millán O; Urtasun N; Brunet M
    Transplant Rev (Orlando); 2009 Apr; 23(2):120-8. PubMed ID: 19298943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokines as predictive biomarkers of alloreactivity.
    Brunet M
    Clin Chim Acta; 2012 Sep; 413(17-18):1354-8. PubMed ID: 22561186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM; Canafax DM; Gillingham KJ; Humar A; Pandian K; Kerr SR; Najarian JS; Matas AJ
    Clin Transplant; 1997 Dec; 11(6):552-7. PubMed ID: 9408683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nutritional and metabolic issues in solid organ transplantation: targets for future research.
    Ward HJ
    J Ren Nutr; 2009 Jan; 19(1):111-22. PubMed ID: 19121784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of different immunosuppressive regimens in the development of posttransplant diabetes mellitus.
    Prokai A; Fekete A; Pasti K; Rusai K; Banki NF; Reusz G; Szabo AJ
    Pediatr Diabetes; 2012 Feb; 13(1):81-91. PubMed ID: 21595806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Solid organ transplant: medication management issues.
    Trofe J; Wimberley S
    J Am Pharm Assoc (Wash); 2000; 40(5 Suppl 1):S48-9. PubMed ID: 11029867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving tolerability of immunosuppressive regimens.
    MacDonald A
    Transplantation; 2001 Dec; 72(12 Suppl):S105-12. PubMed ID: 11833142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients.
    Geissler EK; Hutchinson JA
    Curr Opin Organ Transplant; 2013 Aug; 18(4):408-15. PubMed ID: 23838645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunosuppression: does one regimen fit all?
    Sprangers B; Kuypers DR; Vanrenterghem Y
    Transplantation; 2011 Aug; 92(3):251-61. PubMed ID: 21593703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generic immunosuppression in solid organ transplantation: a Canadian perspective.
    Harrison JJ; Schiff JR; Coursol CJ; Daley CJ; Dipchand AI; Heywood NM; Keough-Ryan TM; Keown PA; Levy GA; Lien DC; Wichart JR; Cantarovich M
    Transplantation; 2012 Apr; 93(7):657-65. PubMed ID: 22267158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of immunosuppression by DNA transfer in transplantation.
    McDaniel DO
    J Long Term Eff Med Implants; 2002; 12(2):131-47. PubMed ID: 12463070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction therapy: why, when, and which agent?
    Krischock L; Marks SD
    Pediatr Transplant; 2010 May; 14(3):298-313. PubMed ID: 20345609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the incidence of infection and malignancy by modifying immunosuppression.
    Soulillou JP; Giral M
    Transplantation; 2001 Dec; 72(12 Suppl):S89-93. PubMed ID: 11833147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.